Abstract:OBJECTIVE:To conduct a systematic review and meta-analysis of randomized controlled trials (RCTs) that have assessed the effect and safety of ursodeoxycholic acid (UDCA), S-adenosylmethionine (SAMe) and UDCA-SAMe combination therapies for intrahepatic cholestasis of pregnancy (ICP).METHODS:Using searching protocols and assessment methods recommended by the Cochrane Collaboration to reduce bias in systematic reviews, the databases of Medline, EMBASE, Cochrane Central Register of Controlled Trials (CCRT), China National Knowledge Infrastructure (CNKI), Chinese BioMedical Literature (CBM) and Wanfang China Online Journals were searched to identify relevant RCTs published from database inception to December 2011.RESULTS:Ten RCTs (of 727 pregnant women) were included in the study and represented a low risk for bias. Compared to the patients who received UDCA monotherapy, those who received UDCA-SAMe combination therapy had significantly lower rates of Cesarean section (odds ratio (OR) =0.45, 95% confidence interval (CI):0.24-0.86), preterm birth (OR=0.36, 95% CI:0.20-0.63), and fetal asphyxia (OR=0.27, 95% CI:0.13-0.56) (all P less than 0.05); however, the UDCA-SAMe therapy did not provide better rates of amniotic fluid pollution (OR=0.38, 95% CI:0.14-1.01) or better new bom weight (mean difference (MD) =397.36, 95% CI:-96.17-890.89). Compared to the patients who received SAMe monotherapy, those who received UDCA-SAMe combination therapy had significantly lower rates of preterm birth (OR=0.39, 95% CI:0.21-0.73), fetal asphyxia (OR=0.23, 95% CI:0.07-0.75), and amniotic fluid pollution (OR=0.41, 95% CI:0.20-0.85) (all, P less than 0.05); however, the UDCA-SAMe therapy did not provide better rates of Cesarean section (OR =0.62, 95% CI:0.27-1.44) or better new bom weight (MD =445.95, 95% CI:-143.51-1035.42). Comparison of the two monotherapies (UCDA vs.SAMe) showed no statistical differences in rates of Cesarean section (OR=0.91, 95% CI:0.47-1.78), preterm birth (OR =0.79, 95% CI:0.49-1.38), fetal asphyxia (OR=0.90, 95% CI:0.38-2.12), and amniotic fluid pollution (OR=1.14, 95% CI:0.61-2.13), as well as of new born weight (MD =-62.86, 95% CI:-157.81-32.09). Six studies reported no side effects.None of the included studies reported use of allocation concealment or blinding.CONCLUSION:UDCA-SAMe combination therapy is better than either UDCA or SAMe monotherapy for improving the outcome of ICP without adverse effects. Large-scale trials with adequate sample sizes and higher quality study design are needed to further confirm the efficiency and safety of UDCA and SAMe for treating ICP.

S-adenosyl-L-methionine in the Treatment of Obstructive Jaundice after Surgical Drainage:A Randomized Multicenter Trial

Clinical study of S-adenosyl-L-methionine in the treatment of malignant obstructive jaundice after surgical drainage

Influence of S-adenosyl-L-methionine on liver protein synthesis in patients with obstructive jaundice

Beneficial Effects of S-adenosyl-L-methionine on Post-Hepatectomy Residual Liver Function: a Prospective, Randomized, Controlled Clinical Trial.

S-adenosylmethionine in Treatment of Cholestasis after Total Parenteral Nutrition: Laboratory Investigation and Clinical Application.

PROTECTIVE EFFECTS OF S-ADENOSYL-L-METHIONINE ON POST-HEPATECTOMY LIVER FUNCTION

A Retrospective, Multi-Center, Post-Marketing Observational Study to Evaluate the Effectiveness of Ademetionine 1,4-Butanedisulfonate Injection (transmetil®) Treatment in Chinese Patients with Intrahepatic Cholestasis Caused by Viral Hepatitis

S-Adenosyl-L-Methionine for the Treatment of Chronic Liver Disease: A Systematic Review and Meta-Analysis

Efficacy of Adenosylmethionine Combined with Si Mo Tang in Treatment of Neonatal Jaundice.

S-Adenosyl-L-Methionine Prevents Total Parenteral Nutrition-Induced Cholestasis in Infected Rats

Effect of S-adenosylmethionine on total parenteral nutrition-associated cholestasis

Feasibility and Efficacy of S-Adenosyl-L-methionine in Patients with HBV-Related HCC with Different BCLC Stages

Protective effect of S-adenosylmethionine on hepatic ischemia-reperfusion injury during hepatectomy in HCC patients with chronic HBV infection

Clinical observation of succinic acid adenosine methionine enteric-coated tablet in treatment of intrahepatic cholestasis during pregnancy

[Meta-Analysis of Ursodeoxycholic Acid and S-adenosylmethionine for Improving the Outcomes of Intrahepatic Cholestasis of Pregnancy].

S-Adenosylmethionine (SAMe) for Liver Health: A Systematic Review

Clinical effect of S-adenosylmethionine on patients with hepatocellular carcinoma resection

The Effect of S-adenomethionine on Early Stage Recovery of Transplanted Liver Function

Preventive Effect of S-adenosyl-L-methionine from Alcoholic Liver Injury in Rats

Effects of S - Adenosylmethionine on Methionine Metabolism and Lipid Peroxidation of Liver from Rats with Ethanol - Induced Liver Injury

The clinical efficacy and safety of different biliary drainage in malignant obstructive jaundice: a meta-analysis